Complement component C5a predicts restenosis after superficial femoral artery balloon angioplasty

Journal of Endovascular Therapy

Volumn 14, Issue 1, 2007, Pages 62-69

  Speidl, Walter S ^a,b   Exner, Markus ^a   Amighi, Jasmin ^a   Mlekusch, Wolfgang ^a   Sabeti, Schila ^a   Kastl, Stefan P ^a,b   Zorn, Gerlinde ^a,b   Maurer, Gerald ^a,b   Wagner, Oswald ^a   Huber, Kurt ^c   Minar, Erich ^a   Wojta, Johann ^a,b   Schillinger, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

Author keywords

Balloon angioplasty; Complement; Restenosis; Superficial femoral artery

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C5A;

ADULT; AGED; ARTICLE; BLOOD VESSEL INJURY; CHEMOTAXIS; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; FEMALE; HUMAN; INFLAMMATION; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; SUPERFICIAL FEMORAL ARTERY;

AGED; ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; COHORT STUDIES; COMPLEMENT C5A; CONSTRICTION, PATHOLOGIC; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; INTERMITTENT CLAUDICATION; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RESEARCH DESIGN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 33847192494     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/06-1946.1     Document Type: Article

References (16)

1. Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J. 2004;25:1679-1687.
2. Welt FG, Edelman ER, Simon DI, et al. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol. 2000;20:2553-2558.
3. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ Res. 2000;86:125-130.
4. Schulman ES, Post TJ, Henson PM, et al. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest. 1988;81:918-923.
5. Nataf S, Davoust N, Ames RS, et al. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol. 1999;162:4018-4023.
6. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94:1147-1155.
7. Okusawa S, Yancey KB, van der Meer JW, et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med. 1988;168:443-448.
8. Kowalski J, Kosmider M, Pawlicki L, et al. Complement activates neutrophils during PICA procedure in patients with unstable angina pectoris. Int J Cardiol. 1997;58:229-240.
9. Pasqui AL, Di Renzo M, Bova G, et al. Changes of some immune functions after percutaneous transluminal coronary angioplasty (PTCA). Int J Clin Pharmacol Res. 1995;15:139-144.
10. Schillinger M, Exner M, Amighi J, et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation. 2003;108:2323-2328.
11. Ranke C, Creutzig A, Alexander K. Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 1992;18:433-440.
12. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg. 2000;31(1 Pt 2):S1-S296.
13. Pietersma A, Kofflard M, de Wit LE, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995;91:1320-1305.
14. Rahel BM, Visseren FL, Suttorp MJ, et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 2003;60:136-140.
15. Turker S, Guneri S, Akdeniz B, et al. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol. 2006;97:198-202.
16. Kubica J, Kozinski M, Krzewina-Kowalska A, et al. Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int J Mol Med. 2005;16:173-180.